OCUGEN, INC. Payments to Acquire Debt Securities, Available-for-sale
OCUGEN, INC. (OCGN) reported Payments to Acquire Debt Securities, Available-for-sale of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-05.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2025-03-05
- OCUGEN, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2024-12-31 was $0.00.
- OCUGEN, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2024-09-30 was $0.00.
- OCUGEN, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2024-06-30 was $0.00.
- OCUGEN, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2024-03-31 was $0.00, a 100.00% decline year-over-year.
- OCUGEN, INC. payments to acquire debt securities, available-for-sale for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- OCUGEN, INC. payments to acquire debt securities, available-for-sale for fiscal 2023 was $3.95M, a 70.26% decline from fiscal 2022.
- OCUGEN, INC. payments to acquire debt securities, available-for-sale for fiscal 2022 was $13.27M.
- OCUGEN, INC. payments to acquire debt securities, available-for-sale for fiscal 2021 was $0.00.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-05 | $0.00 derived: sum of 2 quarters · filed 2025-03-05 | $0.00 derived: sum of 3 quarters · filed 2025-03-05 | $0.00 10-K · filed 2025-03-05 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $0.00 derived: sum of 2 quarters · filed 2024-11-14 | $0.00 10-Q · filed 2024-11-14 | $0.00 derived: sum of 4 quarters · filed 2025-03-05 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $0.00 10-Q · filed 2024-08-08 | $0.00 derived: sum of 3 quarters · filed 2025-03-05 | $0.00 derived: sum of 4 quarters · filed 2025-03-05 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-14 | $0.00 derived: sum of 2 quarters · filed 2025-03-05 | $0.00 derived: sum of 3 quarters · filed 2025-03-05 | $0.00 derived: sum of 4 quarters · filed 2025-03-05 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-05 | $0.00 derived: sum of 2 quarters · filed 2025-03-05 | $0.00 derived: sum of 3 quarters · filed 2025-03-05 | $3.95M 10-K · filed 2025-03-05 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $0.00 derived: sum of 2 quarters · filed 2024-11-14 | $3.95M 10-Q · filed 2024-11-14 | $17.22M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $3.95M 10-Q · filed 2024-08-08 | $17.22M derived: sum of 3 quarters · filed 2024-08-08 | $17.22M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $3.95M 10-Q · filed 2024-05-14 | $17.22M derived: sum of 2 quarters · filed 2024-05-14 | $17.22M derived: sum of 3 quarters · filed 2024-05-14 | $17.22M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $13.27M derived: 10-K 12 month − 10-K 9 month · filed 2024-04-16 | $13.27M derived: sum of 2 quarters · filed 2024-04-16 | $13.27M derived: sum of 3 quarters · filed 2024-04-16 | $13.27M 10-K · filed 2024-04-16 |
| 2022-09-30 | $0.00 derived: 10-K 9 month − 10-K 6 month · filed 2024-04-16 | $0.00 derived: sum of 2 quarters · filed 2024-04-16 | $0.00 10-K · filed 2024-04-16 | |
| 2022-06-30 | $0.00 derived: 10-K 6 month − 10-K 3 month · filed 2024-04-16 | $0.00 10-K · filed 2024-04-16 | ||
| 2022-03-31 | $0.00 10-K · filed 2024-04-16 | |||
| 2021-12-31 | $0.00 10-K · filed 2023-02-28 | |||
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-22 | -$2.00K derived: sum of 2 quarters · filed 2019-03-22 | -$2.00K derived: sum of 3 quarters · filed 2019-03-22 | $8.00M 10-K · filed 2019-03-22 |
| 2017-09-30 | -$2.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | -$2.00K derived: sum of 2 quarters · filed 2018-11-08 | $8.00M 10-Q · filed 2018-11-08 | |
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | $8.01M 10-Q · filed 2018-08-09 | ||
| 2017-03-31 | $8.01M 10-Q · filed 2018-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |